Company intelligence / Profile preview
BioCity Biopharma
Wuxi, Chinaprnewswire.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
SC0062 (ETA antagonist) met primary endpoint in Phase 2 trial for diabetic kidney disease, showing significant reduction in proteinuria. SC0062 has received Breakthrough Therapy Designation from NMPA for IgA nephropathy. Multiple oncology assets in Phase 1/2 development.
- Therapeutic areas
- OncologyNephrology
- Modalities
- Small moleculesmonoclonal antibodiesbispecific antibodiesantibody-drug conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →03
Partnerships
MSD (Merck & Co., Inc.)AstraZeneca
Beyond the preview
Go deeper on BioCity Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioCity Biopharma.